The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Estimating the Risk of Drug-Induced Proarrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes
Abstract
Improved in vitro systems for predicting drug-induced toxicity are needed in the pharmaceutical and biotechnology industries to decrease late-stage drug attrition. One unmet need is an early screen for cardiotoxicity, which accounts for about one third of safety-based withdrawn pharmaceuticals. Herein, the first published report of a high-throughput functional assay employing a monolayer of beating human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) is described, detailing a model that accurately detects drug-induced cardiac abnormalities. Using 96-well plates with interdigitated electrode arrays that assess impedance, the rhythmic, synchronous contractions of the iPSC-CMs were detected. Treatment of the iPSC-CMs with 28 different compounds with known cardiac effects resulted in compound-specific changes in the beat rate and/or the amplitude of the impedance measurement. Changes in impedance for the compounds tested were comparable with the results from a related technology, electric field potential assessment obtained from microelectrode arrays. Using the results from the set of compounds, an index of drug-induced arrhythmias was calculated, enabling the determination of a drug's proarrhythmic potential. This system of interrogating human cardiac function in vitro opens new opportunities for predicting cardiac toxicity and studying cardiac biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 2×
“…would be to reduce, refine, and replace the toxicologist’s reliance on animal testing and increase the relevance of preclinical safety assessment because traditional safety approaches rely heavily on animal models that do not always accurately predict human drug responses (Olson et al., 2000).”
BackgroundREDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
A morphological biosensor for mammalian cells
Giaever, I., & Keese, C. R. (1993) · Nature · doi:10.1038/366591a0 · Cited by 770
Chan, T. Y. K. (2009) · Clinical Toxicology · doi:10.1080/15563650902904407 · Cited by 398
Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes
Braam, S. R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., & Mummery, C. L. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.11.004 · Cited by 368
Physiology and pharmacology of the cardiac pacemaker (“funny”) current
Baruscotti, M., Bucchi, A., & DiFrancesco, D. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.005 · Cited by 338
Ponti, F. D., Poluzzi, E., Cavalli, A., Recanatini, M., & Montanaro, N. (2002) · Drug Safety · doi:10.2165/00002018-200225040-00004 · Cited by 309
HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine
Roy, M.-L., Dumaine, R., & Brown, A. M. (1996) · Circulation · doi:10.1161/01.cir.94.4.817 · Cited by 303
Use and Application of Stem Cells in Toxicology
Davila, J. C. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh100 · Cited by 281
Cited by
Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes
Yang, X., Pabon, L., & Murry, C. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.300558 · Cited by 939
“Another group used hiPSC-CMs as a platform to characterize the proarrythmic potential of 28 different compounds with established cardiac effects.(123) The hiPSC-CMs responded to drug treatment in a manner similar to what has been observed clinically.”
MethodHuman iPSC-based Cardiac Microphysiological System For Drug Screening Applications
Mathur, A., Loskill, P., Shao, K., Huebsch, N., Hong, S., Marcus, S. G., Marks, N., Mandegar, M., Conklin, B. R., Lee, L. P., et al. (2015) · Scientific Reports · doi:10.1038/srep08883 · Cited by 519
Microfluidic heart on a chip for higher throughput pharmacological studies
Agarwal, A., Goss, J. A., Cho, A., McCain, M. L., & Parker, K. K. (2013) · Lab on a Chip · doi:10.1039/c3lc50350j · Cited by 494
iPS cells: a game changer for future medicine
Inoue, H., Nagata, N., Kurokawa, H., & Yamanaka, S. (2014) · The EMBO Journal · doi:10.1002/embj.201387098 · Cited by 405
Navarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P. W., Patlolla, B., Lee, A. S., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000570 · Cited by 302
Denning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293
Translation of Human-Induced Pluripotent Stem Cells
Sayed, N., Liu, C., & Wu, J. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.083 · Cited by 279
Giacomelli, E., Bellin, M., Sala, L., van Meer, B. J., Tertoolen, L. G. J., Orlova, V. V., & Mummery, C. L. (2017) · Development · doi:10.1242/dev.143438 · Cited by 279
Rethinking Differentiation: Stem Cells, Regeneration, and Plasticity
Sánchez Alvarado, A., & Yamanaka, S. (2014) · Cell · doi:10.1016/j.cell.2014.02.041 · Cited by 276
Blinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M. P., Zamora, V., Smith, G., Crumb, W. J., Pang, L., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw200 · Cited by 272
Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues
Feric, N. T., & Radisic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.019 · Cited by 247
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine
Chen, I. Y., Matsa, E., & Wu, J. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.36 · Cited by 191
Tzatzalos, E., Abilez, O. J., Shukla, P., & Wu, J. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.010 · Cited by 162
Ergir, E., Oliver-De La Cruz, J., Fernandes, S., Cassani, M., Niro, F., Pereira-Sousa, D., Vrbský, J., Vinarský, V., Perestrelo, A. R., Debellis, D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22225-w · Cited by 99
Modeling Cardiovascular Diseases with hiPSC-Derived Cardiomyocytes in 2D and 3D Cultures
Sacchetto, C., Vitiello, L., de Windt, L. J., Rampazzo, A., & Calore, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093404 · Cited by 91
Advanced human developmental toxicity and teratogenicity assessment using human organoid models
Li, M., Gong, J., Gao, L., Zou, T., Kang, J., & Xu, H. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113429 · Cited by 84
Mannhardt, I., Eder, A., Dumotier, B., Prondzynski, M., Krämer, E., Traebert, M., Söhren, K.-D., Flenner, F., Stathopoulou, K., Lemoine, M. D., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx081 · Cited by 68
Metadata
- Authors
- Guo, L., Abrams, R. M. C., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., & Kolaja, K. L.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-20
- Volume
- 123
- Issue
- 1
- Pages
- 281-289
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2139658905
- Cited by
- 272
- References
- 38
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.